Predictors of successful neoadjuvant treatment in HER2‑positive breast cancer.

Oncol Lett · 2023 · PMC10472020 · PMID 37664661

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

A recent real-world study by LeVasseur et al ( 18 ) with a median follow-up of 7.5 years revealed a trend for improved BCSS and OS in patients with HER2-positive cancer obtaining pCR, although the finding did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.